tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TSE:RVV Stock Latest News

Revive Therapeutics Updates on Nerve Agent Countermeasure Study
Company AnnouncementsRevive Therapeutics Updates on Nerve Agent Countermeasure Study
14d ago
Revive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
PremiumCompany Announcements
Revive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
26d ago
Revive Therapeutics nears completion of nerve agent countermeasure study
PremiumThe Fly
Revive Therapeutics nears completion of nerve agent countermeasure study
26d ago
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
PremiumCompany Announcements
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
2M ago
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
PremiumCompany Announcements
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
2M ago
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
PremiumCompany AnnouncementsRevive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
3M ago
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
Premium
The Fly
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
3M ago
ATAI
CMND
Revive Therapeutics Explores Bucillamine’s Role in Cancer Treatment
Premium
Company Announcements
Revive Therapeutics Explores Bucillamine’s Role in Cancer Treatment
3M ago
Revive Therapeutics to investigate Bucillamine’s potential in cancer treatment
PremiumThe Fly
Revive Therapeutics to investigate Bucillamine’s potential in cancer treatment
3M ago
Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
PremiumCompany Announcements
Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
4M ago
Revive enters asset purchase agreement for molecular hydrogen program
PremiumThe Fly
Revive enters asset purchase agreement for molecular hydrogen program
4M ago
Revive Therapeutics Aligns with Shareholders in Annual Meeting Decisions
PremiumCompany Announcements
Revive Therapeutics Aligns with Shareholders in Annual Meeting Decisions
4M ago
Revive Therapeutics announces results of annual shareholder meeting
PremiumThe FlyRevive Therapeutics announces results of annual shareholder meeting
4M ago
Revive Therapeutics to Acquire DiagnaMed’s Molecular Hydrogen Program for Neurological Treatments
Premium
Company Announcements
Revive Therapeutics to Acquire DiagnaMed’s Molecular Hydrogen Program for Neurological Treatments
5M ago
Revive Therapeutics enters LOI to acquire DiagnaMed’s molecular hydrogen program
Premium
The Fly
Revive Therapeutics enters LOI to acquire DiagnaMed’s molecular hydrogen program
5M ago
Revive Therapeutics Advances Bucillamine Research for Nerve Agents and Long COVID
PremiumCompany Announcements
Revive Therapeutics Advances Bucillamine Research for Nerve Agents and Long COVID
6M ago
Revive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure
PremiumCompany Announcements
Revive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure
7M ago
Revive Therapeutics provides update on research study of bucillamine
PremiumThe Fly
Revive Therapeutics provides update on research study of bucillamine
7M ago
Revive Therapeutics announces publication on potential of psilocybin
PremiumThe Fly
Revive Therapeutics announces publication on potential of psilocybin
8M ago
Revive Therapeutics Explores Psilocybin for Stroke Treatment
PremiumCompany AnnouncementsRevive Therapeutics Explores Psilocybin for Stroke Treatment
8M ago
Revive Therapeutics provides update on research study of bucillamine
Premium
The Fly
Revive Therapeutics provides update on research study of bucillamine
9M ago
Revive Therapeutics Prioritizes Bucillamine Development
Premium
Company Announcements
Revive Therapeutics Prioritizes Bucillamine Development
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >